Corpus overview


Overview

MeSH Disease

Human Phenotype

Edema (3)

Anxiety (1)

Dyspnea (1)

Palpitations (1)

Pain (1)


Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 3 records in total 3
    records per page




    The reliability and success of peritoneal dialysis during the COVID-19 pandemic

    Authors: Hasan Haci Yeter; Ebru Gok Oguz; Omer Faruk Akcay; Refika Karaer; Emre Yasar; Murat Duranay; Mehmet Deniz Ayli; Galip Guz

    doi:10.21203/rs.3.rs-70335/v1 Date: 2020-09-01 Source: ResearchSquare

    Aim: This study aimed to evaluate the symptoms, changes in laboratory findings during the COVID-19 pandemic, and the effect of depression MESHD on symptoms associated with end-stage kidney disease MESHD in patients with peritoneal dialysis (PD).Methods: This was an observational and cross-sectional study. The patients underwent three different PD modalities, including continuous ambulatory PD, automated peritoneal dialysis, and remote monitoring automated peritoneal dialysis (RM-APD). All patients were asked to complete the clinical assessment form and Beck depression MESHD and anxiety HP anxiety MESHD inventory. Additionally, the last two laboratory evaluations during this period were examined.Results: A total of 123 patients undergoing PD were included. None of the patients were diagnosed with COVID-19 infection MESHD. Serum SERO ferritin, creatinine, phosphorus, albumin and parathyroid hormone levels were significantly elevated in the total study population (p=0.03, p=0.01, p=0.02, p=0.02 and p=0.05, respectively). While calcium, phosphorus, and parathyroid hormone tended to increase in patients with APD or CAPD, they remained stable in patients performing RM-APD. Most of the patients did not experience dyspnea HP dyspnea MESHD, pitting edema MESHD edema HP, difficulty in blood SERO pressure control, palpitation HP, bone muscle pain MESHD pain HP, or peritonitis HP peritonitis MESHD. Moderate to severe depression MESHD was associated with dyspnea HP dyspnea MESHD, weight gain MESHD, fatigue HP fatigue MESHD, palpitation HP, and increased anxiety HP anxiety MESHD.Conclusion: PD is a reliable and successful form of dialysis and can be safely administered even if hospital access is restricted. PD is a safe method of renal replacement therapy to protect patients from COVID-19 infection MESHD. Additionally, RM-APD may be a better choice because it provides more stable bone mineral metabolism. Moreover, evaluating depression MESHD and anxiety HP anxiety MESHD at phone visits may be necessary for accurate clinical assessment.

    Cardiac involvement in COVID-19 patients: mid-term follow up by cardiac magnetic resonance imaging

    Authors: Hui Wang; Ruili Li; Hong Jiang; Zixu Yan; Xinyan Tao; Hongjun Li; Lei Xu

    doi:10.21203/rs.3.rs-57104/v1 Date: 2020-08-11 Source: ResearchSquare

    Background: Coronavirus disease MESHD 2019 (COVID-19) induces myocardial injury MESHD, either direct myocarditis HP myocarditis MESHD or indirect injury due to systemic inflammatory response. Myocardial involvement MESHD has been proved to be one of the primary manifestations of COVID-19 infection MESHD, according to laboratory test, autopsy, and cardiac magnetic resonance imaging (CMRI). However, the middle-term outcome of cardiac involvement MESHD after the patients were discharged from the hospital is yet unknown. The present study aimed to evaluate mid-term cardiac sequelae in recovered COVID-19 patients by CMRIMethods: A total of 47 recovered COVID-19 patients were prospectively recruited and underwent CMRI examination in this study. The CMRI protocol consisted of black blood SERO fat-suppressed T2 weighted imaging (BB-T2WI), T2 star mapping, left ventricle cine imaging, pre- and post-contrast T1 mapping, and late gadolinium enhancement (LGE). Myocardium edema MESHD edema HP and LGE were assessed in recovered COVID-19 patients. The left ventricle ( LV MESHD) and right ventricle (RV) function and LV mass were assessed and compared with normal controls.Results: Finally, 44 recovered COVID-19 patients and 31 normal controls were included in this study. No edema HP edema MESHD was observed in any patient. LGE was found in 13 patients. All LGE lesions were located in the middle myocardium and/or sub-epicardium with a scattered distribution. Further analysis showed that LGE-positive patients had significantly decreased left ventricle peak global circumferential strain (LVpGCS), right ventricle peak global circumferential strain (RVpGCS), right ventricle peak global longitudinal strain (RVpGLS) as compared to non-LGE patients (p<0.05), while no difference was detected between the non-LGE patients and normal controls.Conclusion: Myocardium injury MESHD existed in about 30% of COVID-19 patients. These patients had peak right ventricle strain that decreased at the 3-month follow-up. Cardiac MRI can monitor the COVID-19-induced myocarditis HP myocarditis MESHD progression, and CMR strain analysis is a sensitive tool to evaluate the recovery of left ventricle circumferential contraction dysfunction MESHD and right ventricular dysfunction MESHD.

    An Effective Inhaler Medication In The Treatment Of COVID-19 Associated Pneumonia 

    Authors: Oguz Guvenmez; Huseyin Keskin; Suayip Birinci; Semra Sardaş; Mehmet Salih Sevdi; Kanat Tayfun; Adnan Kazım Usalan; Mujgan Çalışkan; Mehmet Karabay; Burak Ay; Resat Duman; Nilay Duman; Asım Kayıklık; Mehmet Cubuk; Muhammed Furkan Kanca; Ayten Altıntaş; Ahmet Yaser Muslumanoglu

    doi:10.21203/rs.3.rs-53215/v2 Date: 2020-08-04 Source: ResearchSquare

    BackgroundCurrent COVID-19 treatment methods are in the form of oral tablets or intravenous therapy. However, even if the efficacy of these agents is shown in in-vitro studies, the same effect cannot be seen in in-vivo. This is because these treatments are intended to reach the lungs through the blood SERO. However, severe i nterstitial edema MESHD edema HP and blood SERO lood alveolar MESHDbarrier does not allow medications to reach the lungs effectively.ObjectiveIn the new inhaler treatment (N IT) MESHD given in this clinical study, the molecules that have antiviral, antioxidant and anti-inflammatory effects without any t oxicity MESHDwere brought together. This study aims to prevent rapid and effective clinical improvement in COVID-19 patients and prevent any complications related to COVID-19 i nfection. MESHDMethodsThis study approved by The Ministry of Health of Turkey. This clinical study was designed as a multi-center study and performed in Istanbul and Mersin, Turkey. The patients were divided into two groups. Patients were randomly assigned following simple randomization procedures. Eighty patients received the normal treatment protocol, while eighty patients received the new inhalation treatment protocol in addition to the normal treatment protocol. It was applied by connecting the T nebulizer device in intubated patients and with a nebulizer mask in non-intubated patients. Pulse oxygen saturation, respiratory rate, percentage of lung involvement, arterial blood SERO gas, and duration of hospitalization were compared after the treatment.ResultsOne of the most important points of this study is the duration of hospital stay between the two groups. The mean duration of hospitalization in group 1 was 6.5 ± 1.8; in group 2 it was 17.1 ± 2.4. The duration of stay in Group 1 was significantly lower than group 2. (P < 0.05) FOS (Finger oxygen saturation) values were 89.2 ± 4.8 and 96.1 ± 4.7 in group 1 at the end of the 3rd and 7th days, respectively. In group 2, it was 80.3 ± 5.9 and 84.6 ± 4.4. After treatment FOS levels were significantly higher in group 1 for days 3 and 7. (P < 0.05)ConclusionMethods of treatment with multiple molecules should be developed for complex diseases, not single molecule therapy. In this sense, this study is very important as it will bring a new perspective to the scientific world. With the treatment mentioned in the current study; It is important in terms of making a new prophylaxis and therapeutic plan for Covid-19. It is thought that it will be unique in terms of creating a treatment plan with low potential for natural and non-synthetic side effects instead of using toxic and side effects products.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.